Matrix metalloproteinases and atherosclerotic plaque instability.
BACKGROUND
There is growing interest in the role of matrix metalloproteinases in atherosclerosis. Excessive tissue remodelling and increased matrix metalloproteinase activity have been demonstrated during atherosclerotic plaque disruption, a frequent predeterminant of ischaemic cardiac events and stroke. These enzymes represent a potential target for therapeutic intervention to modify vascular pathology.


METHODS
The core of this review is derived from a Medline database literature search.


RESULTS
There is convincing evidence of increased matrix metalloproteinase activity during acute plaque disruption. Evidence for an imbalance promoting increased matrix degradation is less well documented. However, studies of matrix metalloproteinase inhibition in models of vascular disease suggest a potential therapeutic benefit.


CONCLUSIONS
In vivo studies of matrix metalloproteinase inhibition are required to study the potential for reversal or deceleration of the excessive tissue remodelling that accompanies acute plaque disruption.
Loftus
Ian M
IM
Department of Surgery, Leicester University, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX, UK. ianloftus@aol.com
Naylor
A R
AR
Bell
P R F
PR
Thompson
M M
MM
D001161:Arteriosclerosis / Q000201:enzymology* / Q000473:pathology; D015536:Down-Regulation; D006801:Humans; D008666:Metalloendopeptidases / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D013754:Tetracyclines / Q000627:therapeutic use; D019714:Tissue Inhibitor of Metalloproteinases / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000627:therapeutic use
D013754:Tetracyclines; D019714:Tissue Inhibitor of Metalloproteinases; D016212:Transforming Growth Factor beta; D008666:Metalloendopeptidases